Drug Repurposing Market to Reach USD 54.6 Billion by 2034

Introduction
Pune, India, November 2025 - According to Exactitude Consultancy, the Global Drug Repurposing Market is projected to reach USD 54.6 billion by 2034, growing at a CAGR of 8.2% from 2025 to 2034. The rise of computational biology, machine learning models, and real-world data analytics is transforming how pharmaceutical companies discover new therapeutic uses for existing drugs, drastically reducing time-to-market and development costs.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72908

Drug repurposing-also known as drug repositioning or drug reprofiling-leverages existing clinical and safety data to identify new therapeutic indications. It has become a strategic focus for pharmaceutical companies seeking cost-effective innovation and reduced clinical risk.

Key Takeaways
• Market Size: USD 25.1 billion in 2024 → projected USD 54.6 billion by 2034
• CAGR: 8.2% (2025-2034)
• Key Drivers: High R&D costs, AI-enabled discovery, and regulatory support for faster approvals
• Leading Players: Pfizer Inc., GSK plc, Novartis AG, Eli Lilly & Co., Sanofi, Takeda Pharmaceutical, Recursion Pharmaceuticals, BenevolentAI, and Exscientia plc
• Top Sectors: Oncology, neurology, rare diseases, and infectious diseases
• Dominant Region: North America leads with over 42% market share

Market Story
The drug repurposing market has gained strong momentum as the global pharmaceutical industry faces escalating R&D expenditures and longer drug approval timelines. By identifying new indications for approved molecules, companies can bypass early-stage clinical phases, reducing overall costs by up to 60% and development time by nearly five years.

AI platforms such as Recursion, BenevolentAI, and Insilico Medicine are pioneering computational drug discovery pipelines that screen millions of compounds through advanced algorithms and disease modeling. Notably, Pfizer and AstraZeneca have integrated data-driven repurposing frameworks to optimize their oncology and neurology portfolios.

The COVID-19 pandemic further accelerated adoption when drugs like Remdesivir (originally for Ebola) and Dexamethasone (an anti-inflammatory) were successfully repurposed for SARS-CoV-2 treatment-proving the model's effectiveness in emergency scenarios.

Market Segmentation
By Drug Type:
• Approved Drugs
• Clinical Trial Stage Drugs
• Pre-Clinical Drugs

By Therapeutic Area:
• Oncology
• Neurology
• Infectious Diseases
• Autoimmune & Inflammatory Diseases
• Cardiovascular & Metabolic Disorders

By Technology:
• AI and Machine Learning
• Genomic Analysis
• Bioinformatics & Network Pharmacology
• High-Throughput Screening

By End User:
• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Academic Organizations

By Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/72908/drug-repurposing-market

Recent Developments
• October 2025: BenevolentAI and AstraZeneca expanded their AI-based collaboration to include cardiovascular and renal indications for repurposed compounds.
• August 2025: Pfizer announced results from its repurposing initiative identifying novel anti-fibrotic applications for an existing oncology drug.
• June 2025: Recursion Pharmaceuticals raised USD 400 million in a Series E round to scale AI-driven repurposing pipelines.
• April 2025: Exscientia plc entered a partnership with Sanofi to discover new immunology indications using AI-based target prediction models.

Expert Insight
"Drug repurposing represents a paradigm shift in the pharmaceutical industry-where time, cost, and innovation intersect," said Dr. Maya Thornton, Senior Life Sciences Analyst at Exactitude Consultancy. "As AI platforms uncover hidden therapeutic potential in existing compounds, the next decade will witness a renaissance in affordable drug discovery."

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72908

Market Drivers
• Rising R&D costs and declining productivity in traditional drug pipelines
• AI- and data-driven technologies accelerating indication mapping
• Growing focus on rare and orphan diseases with unmet medical needs
• Expanding collaborative models between pharma companies and research institutions

Forecast and Regional Outlook
North America dominates the market due to its strong AI ecosystem, robust clinical trial networks, and favorable regulatory pathways under the FDA's 505(b)(2) program. Europe follows closely, supported by the European Medicines Agency's adaptive licensing frameworks and public-private partnerships.

Asia-Pacific is the fastest-growing region (CAGR more than 9%), propelled by government-backed precision medicine programs in Japan, South Korea, and China, along with the emergence of data-driven biotechs exploring drug repurposing for chronic and rare diseases.

Government & Institutional Initiatives
• U.S. FDA continues to expand the Critical Path Initiative to streamline repurposing approvals.
• EU Horizon Europe Program funds open-access compound libraries for rare-disease research.
• India's Department of Biotechnology (DBT) launched an AI-enabled Drug Repurposing Mission in 2025 to accelerate local pharmaceutical innovation.

Conclusion
The Drug Repurposing Market stands at the forefront of next-generation drug discovery. By merging AI, big data analytics, and clinical insights, the industry is redefining innovation pathways, significantly reducing development risk while expanding therapeutic opportunities. With increasing global collaborations, this market promises to revolutionize drug discovery efficiency and accessibility in the coming decade.

This report is also available in the following languages : Japanese (医薬品再利用市場), Korean (약물 재활용 시장), Chinese (药物再利用市场), French (Marché du repositionnement des médicaments), German (Markt für die Wiederverwendung von Arzneimitteln), and Italian (Mercato del riutilizzo dei farmaci), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72908/drug-repurposing-market#request-a-sample

Related Reports

Antidepressant Drugs Market
https://exactitudeconsultancy.com/reports/49919/antidepressant-drugs-market

Bipolar Disorder Drugs and Treatment Market
https://exactitudeconsultancy.com/reports/53450/global-bipolar-disorder-drugs-and-treatment-market

Milnacipran Hydrochloride Market
https://exactitudeconsultancy.com/reports/58215/global-milnacipran-hydrochloride-market

Transcranial Magnetic Stimulator for Depression Requisition Market
https://exactitudeconsultancy.com/reports/65628/transcranial-magnetic-stimulator-for-depression-requisition-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.